Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9108MR)

This product GTTS-WQ9108MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9108MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10162MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ12586MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ3749MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ7061MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ14712MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ12528MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ6017MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ4047MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW